1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
HUTCHMED (China) Limited

HUTCHMED (China) Limited

HMDCF
HUTCHMED (China) LimitedUS flagOther OTC
2.16
USD
- -
- -
1.86BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.09
0.17
0.33
0.36
0.39
0.32
0.31
0.33
0.45
0.5
0.99
0.74
0.64
Basic EPS, GAAP
0.01
-0.01
0.01
0.02
-0.04
-0.11
-0.16
-0.18
-0.25
-0.43
0.12
0.04
0.53
Free Cash Flow per Basic Share
- -
0.01
-0.02
-0.02
-0.02
-0.06
-0.13
-0.12
-0.28
-0.36
0.22
-0.02
-0.1
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.04
-0.09
-0.06
-0.03
-0.07
-0.18
-0.34
-0.49
-0.66
-1.04
-0.92
-0.87
-0.34
Tangible Book Value per Share
0.2
0.18
0.18
0.34
0.78
0.62
0.46
0.74
1.31
0.75
0.87
0.9
1.45
Basic Weighted Avg Shares
521
526
547
597
617
664
666
698
793
847
850
855
858
Sales/Revenue/Turnover
46
87
178
216
241
214
205
228
356
426
838
630
549
Operating Margin (%)
-2.28
-20.91
-5.48
-21.61
-22.1
-43.27
-71.45
-86.27
-92.1
-95.27
2.57
-6.44
-6.51
Depreciation Expense
1
1
2
2
3
4
5
6
7
9
8
12
13
Net Income, GAAP
6
-7
8
12
-27
-75
-106
-126
-195
-361
101
38
457
Effective Tax Rate (%)
10.43
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.73
- -
12.76
Profit Margin (%)
12.87
-8.37
4.49
5.41
-11.08
-34.94
-51.75
-55.15
-54.66
-84.62
12.03
5.99
83.3
Working Capital
-11
15
8
72
328
285
204
372
900
486
694
690
1,252
LT Debt
- -
27
27
27
- -
27
30
33
7
23
51
64
70
Total Equity
105
98
102
204
485
412
313
519
1,040
637
743
772
1,251
Return on Invested Capital (%)
-0.68
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.65
- -
-2.81
Return on Capital (%)
20.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
-13.34
- -
-111.25
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.82%
28.85%
62.11%
Free Cash Flow
65.28%
68.03%
409.32%
Net Income, GAAP
101.86%
212.15%
1,111.03%
Sales/Revenue/Turnover
16.33%
26.94%
-12.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
838
2024
- -
- -
- -
- -
630
2025
- -
- -
- -
- -
549

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.12
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.53

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Chig Fung Cheng
Full Time Employees
1,796
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Cheung Kong Center Hong Kong Hong Kong
IPO Date
Apr 17, 2014
CIK
0001648257
Website
hutch-med.com
Similar Companies
FSD Pharma Inc. (HUGE.CN)
Wockhardt Limited (WOCKPHARMA.BO)
Epsilon Healthcare Limited (EPN.AX)
Pure Global Cannabis Inc. (PRCNF)
SciClone Pharmaceuticals, Inc. (SCLN)
Fifty 1 Labs, Inc. (FITY)
Business
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) is an innovative commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. Founded in 2000 and headquartered in Hong Kong with primary operations in mainland China, the company offers marketed products including Elunate (fruquintinib), a selective oral VEGFR inhibitor for metastatic colorectal cancer; Orpathys (savolitinib), a selective oral MET inhibitor for non-small cell lung cancer with MET exon 14 skipping mutations; Sulanda (surufatinib), an angio-immuno kinase inhibitor targeting VEGFR, FGFR, and CSF-1R for advanced neuroendocrine tumors; and Fruzaqla (fruquintinib), approved in the US, Europe, and Japan for metastatic colorectal cancer. It maintains a robust pipeline of novel drug candidates from its in-house discovery engine, emphasizing oncology and immunology treatments with global market potential, and operates a profitable commercial platform for prescription drugs and consumer health products primarily in China while expanding internationally through partnerships. Recent developments include Takeda’s US launch of Fruzaqla generating initial sales recognition, collaboration progress with Inmagene on IMG-007 (anti-OX40 antibody) and IMG-004 (BTK inhibitor) yielding a 7.5% equity stake for HUTCHMED, updated 2025 revenue guidance of $270-350 million for oncology/immunology reflecting milestone phasing, and strategic emphasis on partnering with multinational firms like AstraZeneca, Lilly, and Takeda amid portfolio expansion toward six or seven marketed oncology drugs in China by year-end.